How PBI/Gordon Companies leveraged our Sirolimus API Market report
VM Intelligence · Sample preview · Healthcare and Pharmaceuticals · Forecast 2027–2033
Alzheimer's Disease Drug Market
- By Drug Class: Cholinesterase Inhibitors, NMDA Receptor Antagonists, Amyloid Beta-Targeting Agents, Tau Protein Inhibitors, Neuroprotective Agents
- By Stage of Alzheimer's Disease Treated: Mild Alzheimer's Disease, Moderate Alzheimer's Disease, Severe Alzheimer's Disease
- By Mechanism of Action: Acetylcholinesterase Inhibition, Glutamatergic Regulation, Amyloid Beta Plaque Reduction, Tau Protein Aggregation Inhibition, Anti-inflammatory Action
- By Formulation: Oral Tablets, Injectable Solutions, Transdermal Patches, Intranasal Sprays
- By Therapeutic Approach: Symptomatic Treatment, Disease-Modifying Therapies, Combination Therapies
Key Highlights
A snapshot of what the full report proves- 01 Market size - $X,XXX.XM global market in 2025 - the verified base-year revenue. Executive Summary →
- 02 Forecast - Full 2033 market projection modelled inside - unlock the forecast value to see where the market lands. Market Outlook →
- 03 Growth - Year-by-year CAGR across 2027–2033 - unlock the growth rate and the full model. Market Outlook →
- 04 Leading segment - Cholinesterase Inhibitors leads By Drug Class at XX% share. Market, by Service Type →
- 05 Global coverage - Sized across 5 regions and 20 countries, each broken out by segment. Market, by Geography →
- 06 Competitive landscape - 12 companies profiled with SWOT, benchmarking and market-share analysis. Company Profiles →
Inside the Report
12 chapters · 286 pages- 01 Introduction Definition, segmentation & scope p.12 →
- 02 Research Methodology How the numbers were built p.20 →
- 03 Executive Summary The market in one chapter p.34 →
- 04 Market Outlook Drivers, restraints, trends p.66 →
- 11 Competitive Landscape 5 sections p.178 →
- 12 Company Profiles 12 players: SWOT & benchmarking p.186 →
Full report · locked preview
Everything inside the Alzheimer's Disease Drug Market report
A complete, evidence-based study - 12 chapters and 120 sections covering market size, segmentation across 5 axes, regional analysis and 12 company profiles, forecast to 2033.
Segmentation covered
Drug Class 5
Stage of Alzheimer's Disease Treated 3
Mechanism of Action 5
Formulation 4
Therapeutic Approach 3
Companies profiled
Biogen Inc.
Eli Lilly and Company
Roche Holding AG
Novartis AG
ACADIA Pharmaceuticals Inc.
Axsome Therapeutics Inc.
Cassava Sciences Inc.
Anavex Life Sciences Corp.
H. Lundbeck A/S
Otsuka Pharmaceutical Co. Ltd.
Green Valley Pharmaceuticals
BioArctic AB
Verified · Analyst-reviewed · No payment to preview
Trusted & certified by
★★★★★ Excellent
★★★★★ Excellent
12 players profiled - tiered by revenue contribution, footprint and R&D capability.
ACE Matrix · p.153 →Biogen Inc.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.155 →Eli Lilly and Company
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.160 →Roche Holding AG
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.166 →Novartis AG
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.173 →ACADIA Pharmaceuticals Inc.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.178 →Axsome Therapeutics Inc.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.184 →Cassava Sciences Inc.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.191 →Anavex Life Sciences Corp.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.196 →H. Lundbeck A/S
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.202 →Otsuka Pharmaceutical Co. Ltd.
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.209 →Green Valley Pharmaceuticals
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.214 →BioArctic AB
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.220 →Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Global · 2025–2033
$1,345M by 2033 · 3.9% CAGR
Market estimates & forecast (USD Million)
Fig. 15 · p.34 →Segment mix, 2033 (% share)
Fig. 16 · p.35 →- Cholinesterase Inhibitors47.5
- NMDA Receptor Antagonists14.8
- Amyloid Beta-Targeting Agents13.2
- Tau Protein Inhibitors6.6
- Neuroprotective Agents17.9
Regions, 2025 → 2033 (USD Mn)
§6.1 · p.75 →North America$326.9M → $473.9M · 4.8%
Europe$227.8M → $284.5M · 2.8%
Asia Pacific$208.0M → $303.4M · 4.8%
Latin America$128.8M → $158.2M · 2.6%
Middle East and Africa$99.1M → $135.2M · 4.0%
Top countries, 2033 (USD Mn)
§6.2 · p.78 →Year-over-year growth (%)
§3.12 · p.44 →3.862026
3.872027
3.882028
3.882029
3.892030
3.922031
3.922032
3.932033
CAGR by region (%)
Fig. 22 · p.71 →Market share by company, 2033 (%)
Fig. 41 · p.152 →- Biogen Inc.18.8
- Eli Lilly and Company16.0
- Roche Holding AG3.8
- Novartis AG12.3
- ACADIA Pharmaceuticals Inc.11.6
- Axsome Therapeutics Inc.9.5
- Others28.0
Segment contribution to growth (%)
Fig. 18 · p.39 →Drug Class11.8%
Stage of Alzheimer's Disease Treated24.9%
Mechanism of Action20.0%
Formulation21.4%
Therapeutic Approach22.0%
Competitive positioning (ACE matrix)
Fig. 40 · p.153 →Adoption & penetration (% of addressable)
Fig. 12 · p.31 →Revenue by application (USD Mn)
§5.3 · p.62 →Demand by end-use (USD Mn)
§5.4 · p.66 →Average selling price trend (index, 2025=100)
Fig. 27 · p.58 →Top companies by revenue, 2033 (USD Mn)
Fig. 42 · p.155 →Revenue by region, 2033 (%)
Fig. 20 · p.70 →- North America35.0
- Europe21.0
- Asia Pacific22.4
- Latin America11.7
- Middle East and Africa10.0
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
8 players benchmarked across 6 dimensions — scored 0–100 from share, portfolio, reach, innovation, financials and installed base. Methodology · §8.1 · p.160 →
Competitive scorecard (score 0–100)
Table 31 · p.161 →| Company | Market share | Product portfolio | Geographic reach | Innovation & R&D | Financial strength | Customer base | Composite |
|---|---|---|---|---|---|---|---|
| Biogen Inc. | 83 | 81 | 98 | 95 | 75 | 97 | 88 |
| Eli Lilly and Company | 88 | 77 | 75 | 86 | 69 | 72 | 78 |
| Roche Holding AG | 87 | 67 | 65 | 76 | 82 | 81 | 76 |
| Novartis AG | 80 | 76 | 59 | 70 | 70 | 69 | 71 |
| ACADIA Pharmaceuticals Inc. | 74 | 57 | 73 | 52 | 67 | 64 | 65 |
| Axsome Therapeutics Inc. | 62 | 60 | 56 | 56 | 58 | 55 | 58 |
| Cassava Sciences Inc. | 43 | 58 | 61 | 48 | 66 | 53 | 55 |
| Anavex Life Sciences Corp. | 52 | 56 | 50 | 49 | 47 | 46 | 50 |
Vendor positioning (presence × innovation)
Fig. 43 · p.163 →Strengths profile (top 3 players)
Fig. 44 · p.165 →- Biogen Inc.
- Eli Lilly and Company
- Roche Holding AG
Capability coverage
§8.3 · p.168 →| Company | Global delivery | R&D depth | Digital platform | Sustainability | After-sales | Custom solutions |
|---|---|---|---|---|---|---|
| Biogen Inc. | ✓ | ◐ | ✓ | ✓ | ✓ | ◐ |
| Eli Lilly and Company | ✓ | ◐ | ◐ | ◐ | ◐ | − |
| Roche Holding AG | ✓ | ◐ | ◐ | ✓ | ✓ | ◐ |
| Novartis AG | ◐ | ◐ | ◐ | ◐ | ✓ | − |
| ACADIA Pharmaceuticals Inc. | ◐ | − | ◐ | − | ◐ | − |
| Axsome Therapeutics Inc. | ✓ | − | ◐ | − | ◐ | ◐ |
| Cassava Sciences Inc. | − | ◐ | ◐ | − | − | − |
| Anavex Life Sciences Corp. | − | − | − | − | ◐ | − |
✓ Full ◐ Partial − Limited
Overall competitive index (composite, ranked)
Fig. 45 · p.170 →1Biogen Inc.88
2Eli Lilly and Company78
3Roche Holding AG76
4Novartis AG71
5ACADIA Pharmaceuticals Inc.65
6Axsome Therapeutics Inc.58
7Cassava Sciences Inc.55
8Anavex Life Sciences Corp.50
Competitive tiers
§8.4 · p.172 →Leader2
Set the pace on share, breadth and innovation.
Biogen Inc.Eli Lilly and Company
Challenger2
Strong scale, closing on the leaders.
Roche Holding AGNovartis AG
Contender2
Focused players with pockets of strength.
ACADIA Pharmaceuticals Inc.Axsome Therapeutics Inc.
Niche2
Specialists in a single segment or region.
Cassava Sciences Inc.Anavex Life Sciences Corp.
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Go-to-market strategy
Land Drug Class in North America, then scale across Alzheimer's Disease Drug Market — a $351M beachhead inside a $6.11B market.
Beachhead (SOM)$351Mobtainable near-term
Serviceable (SAM)$2.17Breachable market
Primary motionDirect + partner-ledgo-to-market
Time to scale4 Qto full motion
Ideal customer profile (who to sell to)
§GTM 1 · p.190 →Champion91 fit
Cholinesterase Inhibitors
Best fit — highest urgency & budget in Drug Class.
Economic buyer80 fit
NMDA Receptor Antagonists
Strong fit — clear ROI and a fast path to value.
End user66 fit
Amyloid Beta-Targeting Agents
Emerging fit — growing demand, longer sales cycle.
Market-entry sequence (beachhead → scale)
Fig. GTM 1 · p.192 →Beachhead · 2025–2026
Win Drug Class in North America
Concentrated ICP, fastest proof and references.
Expand · 2026–2028
Add Stage of Alzheimer's Disease Treated & next regions
Repeat the motion in adjacent, look-alike segments.
Scale · 2028–2033
Full-market coverage + Mechanism of Action
Multi-channel, platform & ecosystem plays.
Channel mix (routes to market)
§GTM 3 · p.195 →Direct sales46%
Partner / channel28%
Digital / self-serve19%
Marketplaces6%
Positioning & messaging
§GTM 2 · p.194 →For Drug Class leaders who need defensible market intelligence, VM Intelligence is the fastest, source-cited way to size, segment and win Alzheimer's Disease Drug Market — unlike generic, static research.
Live & source-cited
Every figure triangulated from 600K+ sources and traceable.
Ready in minutes
A full, tailored report compiled on demand — not weeks.
Scope you control
Pick the chapters, regions and companies that matter.
GTM funnel & unit economics (conversion · CAC / LTV)
Fig. GTM 2 · p.198 →Awareness100%
Marketing qualified40%
Sales qualified24%
Evaluation13%
Closed-won8%
$20.5KCAC
$97KLTV
4.7:1LTV : CAC
< 5 moCAC payback
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Investment thesis
Alzheimer's Disease Drug Market is a durable-growth opportunity — $2.30B by 2033, compounding at 7.5%.
TAM · 2025$1.29Btoday
TAM · 2033$2.30Bforecast
CAGR7.5%2027–2033
Cumulative$15.8Brevenue opportunity
Market opportunity (TAM · SAM · SOM)
Fig. 3 · p.14 →TAM$2.30BTotal addressable market
SAM$863MServiceable available market
SOM$156MServiceable obtainable market
Growth trajectory (USD Million)
Fig. 4 · p.16 →Why invest now
§2.1 · p.10 →7.5% CAGR
Demand compounds through 2033, outpacing GDP across Drug Class.
Global tailwinds
North America leads today; fastest gains coming from emerging regions.
Structural shift
Adoption in Drug Class moving from early to mainstream — durable secular demand.
Consolidation upside
12+ players, no runaway leader — room to build scale and roll up share.
Investment highlights
§2.2 · p.12 →$2.30BLarge & growingTAM by 2033 at 7.5% CAGR
$863MServiceable nowreachable with today’s model
$156MBeachhead winobtainable near-term share
12+Fragmented fieldplayers — consolidation runway
Return scenarios (2033 market value)
Fig. 6 · p.22 →$1.80BBear4.9% CAGR
$2.30BBase7.5% CAGR
$2.95BBull9.9% CAGR
Key risks & mitigants
§9.1 · p.180 →- Input-cost volatilityLong-term supply contracts & hedging
- Regulatory / policy shiftsDiversified exposure across 5 regions
- Technology disruptionR&D pipeline & Stage of Alzheimer's Disease Treated optionality
- Customer concentrationBroaden installed base beyond top accounts
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Board pack · executive summary
Alzheimer's Disease Drug Market — a $1.47B market by 2033. Plan: grow share from 8.9% to 17.2%.
Market size · 2033$1.47Btotal addressable
Market CAGR7.4%2027–2033
Target share17.2%from 8.9% today
Revenue ambition$252Mby 2033
Strategic scorecard (current vs 2033 target)
Table 1 · p.6 →| Objective | Current | Target · 2033 | Status |
|---|---|---|---|
| Market share | 8.9% | 17.2% | On track |
| Revenue | $135M | $252M | Ahead |
| Geographic coverage | 2 of 5 regions | 5 of 5 regions | At risk |
| Segment coverage | 3 of 5 axes | 5 of 5 axes | Behind |
| Gross margin | 36.4% | 41.3% | On track |
| Customer retention | 85.3% | 92.5% | At risk |
Where to play (strategic priorities)
§1.2 · p.8 →1
Lead segment
Win in Drug Class
Largest revenue pool and fastest secular demand — concentrate to build share here first.
2
Geographic
Expand across North America & beyond
Deepen the leading region, then scale into the fastest-growing emerging markets.
3
Adjacency
Build Stage of Alzheimer's Disease Treated capability
A defensible second engine — invest in Stage of Alzheimer's Disease Treated to widen the moat and cross-sell.
Strategic roadmap (2025–2033)
Fig. 1 · p.10 →Phase 1 · Foundation
2025–2027
- Secure core Drug Class share
- Fix unit economics
- Stand up data & ops
Phase 2 · Scale
2028–2030
- Enter new regions
- Launch Stage of Alzheimer's Disease Treated
- Selective M&A
Phase 3 · Lead
2031–2033
- Category leadership
- Premium mix & margin
- Platform & ecosystem
Board decisions & asks
§1.4 · p.14 →- Approve $35M capacity & capability investment
- Greenlight bolt-on M&A in Stage of Alzheimer's Disease Treated
- Authorise North America expansion plan
- Fund R&D program for Drug Class leadership
Risk watchlist (RAG)
§9 · p.180 →- Demand / macro slowdownBehind
- Competitive share lossOn track
- Input-cost & supply riskOn track
- Regulatory / policy changeAhead
- Execution & talentAt risk
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Sales deck · value proposition
Win the Alzheimer's Disease Drug Market conversation — a $3.74B market you can size, segment and defend in minutes.
Market size · 2033$3.74Btotal opportunity
Growth7.6%CAGR to 2033
Addressable buyers1,382+accounts in scope
Typical ROI7×in year one
Who buys (target personas)
§1.1 · p.4 →Product / BU leader
Head of Drug Class
Goal Grow share in Drug Class
Pain Blind spots on demand, pricing & competitors.
Regional GM
North America lead
Goal Prioritise the right markets
Pain No granular, country-level view of the market.
M&A / strategy
Strategy & Corp Dev
Goal Find where to invest or acquire
Pain Slow, inconsistent third-party research.
From pain to solution
§1.2 · p.6 →Decisions made on stale, generic dataLive, source-cited figures, continuously updated
Weeks waiting on a research vendorA full report compiled in minutes
No view of competitors or whitespaceCompany profiles, ACE matrix & benchmarking
Hard to defend the numbers internallyEvery figure traceable to its original source
The business case (ROI)
Fig. 2 · p.9 →7×return on cost, year one
< 2 mopayback period
$98K+research cost avoided
10×faster than a custom study
Time to insight
Cost to run
Risk of a wrong call
Why buyers trust it (proof points)
§1.3 · p.12 →600K+source studies indexed
100%analyst-reviewed
12+players profiled in this market
Coverage includes
Biogen Inc.Eli Lilly and CompanyRoche Holding AGNovartis AGACADIA Pharmaceuticals Inc.Axsome Therapeutics Inc.Cassava Sciences Inc.Anavex Life Sciences Corp.+4 more
Objection handling
§1.4 · p.14 →“We already have market data.”
This triangulates 600K+ sources into one current, defensible view — not another silo.
“How do we know it’s accurate?”
Analyst-reviewed, and every figure is source-cited and traceable to its origin.
“It’s not in the budget.”
A fraction of a single analyst-day — and it pays back on the first decision it informs.
“We need it tailored to us.”
Choose the chapters, regions and companies before you build — you only pay for scope.
What you get (packages)
§1.5 · p.16 →Report
- Full multi-chapter report
- Market size, share & forecast
- Segment & regional breakdowns
- PDF + editable Excel + PPT
Most popular
Report + Add-ons
- Everything in Report
- Interactive Visualizer
- Competitive benchmarking
- Investor / board / sales decks
Enterprise
- Multiple reports & markets
- Team seats & sharing
- Analyst support & custom scope
- API / data-feed options
Almost there
Access your Alzheimer's Disease Drug Market report
Sign in to unlock the full report - it’s compiled live and ready in minutes.
or continue with your email
Your report is ready to access
Alzheimer's Disease Drug Market Report is ready
Verify your email to unlock it. We sent a 6-digit code to your inbox.
That code is invalid or expired. Please try again.
Trusted by strategy, finance & consulting teams
Related Reports
Healthcare and Pharmaceuticals · scroll →Embolization Particle Market
Market size, share, segmentation and regional forecast.
$6.1B market · 2025 base year
View reportNalbuphine Hydrochloride Market
Market size, share, segmentation and regional forecast.
$3.7B market · 2025 base year
View reportNalbuphine HCL Market
Market size, share, segmentation and regional forecast.
$3.1B market · 2025 base year
View reportCheckpoint Inhibitors for Treating Cancer Market
Market size, share, segmentation and regional forecast.
$4.4B market · 2025 base year
View reportAdhesive Bandages Market
Market size, share, segmentation and regional forecast.
$5.5B market · 2025 base year
View reportAlginate Wound Dressing Market
Market size, share, segmentation and regional forecast.
$2.6B market · 2025 base year
View reportSilver Antimicrobial Dressing Market
Market size, share, segmentation and regional forecast.
$562M market · 2025 base year
View reportSilver Advanced Wound Dressing Market
Market size, share, segmentation and regional forecast.
$2.6B market · 2025 base year
View reportAmpicillin Market
Market size, share, segmentation and regional forecast.
$5.3B market · 2025 base year
View reportCell Culture Protein Surface Coatings Market
Market size, share, segmentation and regional forecast.
$1.3B market · 2025 base year
View reportAntacid Market
Market size, share, segmentation and regional forecast.
$4.6B market · 2025 base year
View reportAmyotrophic Lateral Sclerosis (ALS) Treatment Market
Market size, share, segmentation and regional forecast.
$396M market · 2025 base year
View reportThe showdown
Custom-built vs. off-the-shelf
Scroll to watch them go head-to-head
WinnerVMR Custom Report
- Tailored to your exact scope
- Delivered in minutes
- Live, always-current data
- Fully editable data (XLSX)
- You choose the companies
- Source-cited & traceable
Off-the-shelf PDF
- Generic, one-size template
- Waits 2–5 days
- A fixed snapshot in time
- Locked, flat PDF
- Preset company list
- Opaque sourcing
Customer Testimonials
Proof from industry leaders who rely on us
These stories come from the executives who depend on VMR’s intelligence for market entry, expansion, assessment, and planning. Their outcomes and experiences reflect our commitment to clarity.
600,000+source studies indexed
100%analyst-reviewed
Every figuresource-cited & traceable
In their words
Watch clients tell their story
How VMR helped University of Limerick with Anesthesia Monitoring Devices
How VMR helps brands expand into Africa & emerging markets
Unlock your GTM strategy: an Elsewedy Electric success story
Beyond sales data: layering NielsenIQ data to support strategy
How VMR became the trusted partner for United Alloy
Questions, answered
How is the research actually conducted?
Every report is compiled from VMR’s continuously-updated intelligence across 600,000+ source studies - primary interviews, company filings, trade data, and government & industry databases. Figures are triangulated across multiple credible sources, then reviewed by a research analyst before your report is delivered.
What exactly do I get inside the report?
A full multi-chapter study: market definition & methodology, executive summary, market outlook (drivers, restraints, trends, Porter’s Five Forces), segment deep-dives, regional & country breakdowns, competitive landscape, and a full profile for every company you select - with interactive charts and data tables throughout.
How accurate are the numbers, and can I trust them?
Market sizing is reconciled across leading sources (Gartner, BCG, MarketsandMarkets, government bodies and more), with outliers removed and a confidence-graded median used for the base year. Every figure is source-cited and traceable to its origin, and an analyst validates the model before delivery.
Can I customise the chapters, regions and companies?
Yes. Choose exactly the chapters, regions and countries, and the companies you want benchmarked before you build - then adjust your selection and recompile anytime from your account. You only pay for the scope you need.
What formats do I receive, and is the data editable?
Every report is readable online in full. Downloadable formats are available as optional $99 add-ons: a formatted PDF and a fully editable XLSX containing all underlying data tables - so you can re-chart, re-model, or drop any figure straight into your own deck.